Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15726083 | 0.95 | MMP8 (0.49) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL6711568 | 0.91 | MMP8 (0.57) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL2050344 | 0.90 | MMP8 (0.53) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL7696784 | 0.88 | ESR1 (0.51) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL2426124 | 0.87 | MMP8 (0.54) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL901733 | 0.87 | EPHX2 (0.50) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL2429506 | 0.87 | PPARG (0.50) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL3764833 | 0.87 | MMP8 (0.50) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL856250 | 0.86 | MMP8 (0.69) | MMP8MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL854302 | 0.85 | LDHA (0.63) | MMP8MEN1KMT2AALDH1A1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0180745-A1 | Acylacetate and amidine intermediates for pyrimidone compounds, and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2007144625-A1 | 2-OXO-2H-CHROMENE COMPOUNDS | ARGENTA DISCOVERY LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1432720-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003020737-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
| US-4588749-A | ANTIOBESITY AND HYPOGLYCEMIC AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-05-13 | — | — | US | disclosed |
| EP-0040000-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | MMP8 1671/4885MEN1 3100/4885KMT2A 4016/4885 |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | SLC5A2, SLC5A1, SLC2A1 | MMP8 4196/4885MEN1 4727/4885KMT2A 2054/4885 |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | MMP8 1240/4885MEN1 4669/4885KMT2A 3899/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | MMP8 1671/4885MEN1 3100/4885KMT2A 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.